Is Red Light Therapy Worth It for PCOS? What the Evidence Actually Shows

(PCOSguides may earn a commission on some links below at no extra cost to you — full affiliate disclosure.)

Is red light therapy actually worth it for PCOS?

Not for PCOS itself, based on what has actually been published. Zero human clinical trials have tested whether red light therapy changes a PCOS-relevant endpoint — cycle regularity, androgen levels, insulin sensitivity, or ovulation — in a real patient. Every PCOS-specific study that exists was conducted in rats or in oocytes cultured in a lab dish, not in a woman using a device at home or in a clinic. Marketing copy for red light panels frequently cites photobiomodulation research from unrelated fields — skin, wound healing, hair — to imply a broader hormonal or metabolic benefit that has not been tested in this condition. That gap between what has been studied and what is implied is the reason this page exists.

What has actually been studied in PCOS, and in what?

Three animal studies and one laboratory study make up the entire PCOS-specific evidence base as of this writing, and stating the species and setting for each matters more than the headline finding.

A 2023 study induced PCOS in rats with estradiol valerate, then treated them with three different low-level laser doses (1, 2, and 6 J/cm²) and found the 2 J/cm² group’s testosterone, LH, and FSH levels moved closest to the untreated control group — a dose-dependent hormonal effect, but entirely in rats, with the authors themselves concluding more work is needed just to establish an optimal dose in that model. A separate 2019 study similarly found photobiomodulation improved measures of ovarian activity in PCOS-induced rats, and a 2017 study compared red (630 nm) and near-infrared (810 nm) low-level lasers against the fertility drug clomiphene in rat ovarian tissue, finding the near-infrared group showed a significant increase in follicle production where the visible-red group did not reach significance.

The one study closest to human tissue is still not a clinical trial: a 2023 study took oocytes retrieved from women with PCOS undergoing infertility treatment, cultured them outside the body, and found photobiomodulation reduced markers of cell death and stress (caspase-3, ROS) in those cultured cells. The cells came from PCOS patients; the treatment and every measurement happened in a lab dish, not in a living patient, and no clinical outcome — a cycle, a pregnancy, a lab value drawn from blood — was measured.

Does red light therapy do anything, in anyone?

Yes, in other conditions — which is exactly what gets borrowed to imply a PCOS benefit that was never tested. Photobiomodulation follows what researchers call a biphasic dose response: a 2009 review of the underlying dosimetry describes low-level light therapy’s effects as following an “Arndt-Schulz” curve, where too little light does nothing and too much light reverses or eliminates the benefit entirely — dose is not a minor detail here, it is the variable that decides whether any biological effect happens at all, in any condition it has been tested in.

The clearest human evidence, for a completely different indication than PCOS, is hair regrowth. A double-blind, sham-controlled randomized trial tested a specific 655 nm laser-and-LED helmet device against a sham device in 47 women with androgenetic (pattern) hair loss, delivering 67 J/cm² per 25-minute session, and found a 37% increase in hair count in the active group compared with sham after 16 weeks, with no adverse events reported in either group. That specific device later received FDA clearance for that specific indication — hair growth in androgenetic alopecia — which is a real, narrow, honestly-earned result. It is not evidence about PCOS, cycles, androgens, or insulin. It is evidence about hair follicles responding to a precisely dosed light source, in a trial that had nothing to do with diagnosing or treating PCOS.

Where might red light therapy have a genuine, narrow role for someone with PCOS?

The one place the evidence actually reaches is PCOS-related hair thinning, because androgenetic hair loss is androgenetic hair loss regardless of what raised the androgen level in the first place — the Lanzafame trial above was not conducted in women with PCOS, but the follicle-level mechanism it tested does not require a PCOS diagnosis to apply. That is a mechanism-level “may transfer,” not a PCOS-specific result, and it says nothing about acne, cycles, or metabolic markers. Red and blue light combinations are separately used in some dermatology settings for mild acne, an indication some consumer devices are cleared for — but that is a skin-inflammation effect, not a hormonal one, and it does not treat the androgen excess driving PCOS acne in the first place.

What’s the difference between a wellness panel and a clinical device?

Almost entirely the dose, and dose is set by irradiance (power per area) multiplied by exposure time. A clinical or research-grade photobiomodulation device delivers a documented, published irradiance and total energy dose — the Lanzafame trial’s device delivered a specific 67 J/cm² over a fixed 25 minutes, a number that came from the manufacturer’s own device specification and was verified as part of the trial design. A consumer full-body or facial panel sold as a wellness product may or may not publish an equivalent number clearly, and panels vary enormously in output power, distance-to-skin assumptions, and session length — all of which change the actual dose delivered far more than the brand name does. Because of the biphasic dose-response curve above, a panel that under- or over-doses relative to what a study actually tested is not simply “a weaker version” of that study’s result — it may produce no effect, or a different one, at a different dose entirely.

Is it safe? What about my eyes?

Protect your eyes every session, without exception. Red and near-infrared wavelengths penetrate tissue specifically because they are less readily absorbed at the surface — the same property that makes them of research interest for skin and hair also means direct, unprotected, close-range exposure to the eye is not a risk to casually dismiss. Manufacturers of full-body and facial panels near-universally instruct users to wear the protective eyewear provided or keep eyes closed and shielded during a session; treat that instruction as a hard rule, not a suggestion, and do not use a panel that ships without one. Beyond eye protection, reported side effects in the human trial above were minimal — no adverse events in either the active or sham group — but that trial used one specific, dosed device for one specific indication, not the wide range of consumer panels on the market at uncontrolled doses.

Is the cost justified by the evidence?

For PCOS specifically, no — and this is a genuinely expensive category to get wrong. Handheld devices, full-body panels, and in-studio sessions span a wide price range, and current pricing changes often enough that this page won’t guess at it; check the specific product’s own listing before buying, and weigh that number against the dose data above, not against the brand’s marketing claims. Spending money on a device because its marketing references “photobiomodulation research” is spending against evidence that exists in a different population, a different tissue, and — for the PCOS-specific studies above — a different species. If your goal genuinely is hair regrowth, the Lanzafame-style device class at least has a matching human trial and an FDA clearance for that specific use; if your goal is a PCOS cycle, androgen, or insulin outcome, no current product purchase is backed by evidence at that level, regardless of price.

Who this will not work for

If you are buying a red light panel expecting it to regulate your cycle, lower your androgens, or improve insulin resistance, the current evidence does not support that expectation at any price point — the entire PCOS-specific evidence base is preclinical. If you have a diagnosed eye condition or are on a medication that increases photosensitivity, talk to a clinician before adding any light-based device, and always use the eye protection provided regardless. And if what you’re actually trying to treat is PCOS-driven acne or hirsutism rather than hair thinning, red light therapy is not the evidence-backed option for either — a dermatologist-guided treatment plan or an actual hair-removal device built for that job rests on a larger and more relevant evidence base than a wellness panel does.

This condition was also renamed in 2026: a global consensus of more than 50 organisations adopted polyendocrine metabolic ovarian syndrome, or PMOS, in place of PCOS. Nothing about the evidence above changes with the name; this article uses PCOS because that is what most readers are searching.

More evidence-first product comparisons like this one sit in the reviews section, including a documented look at at-home laser hair removal for PCOS-related hirsutism and a comparison of skincare products for PCOS acne.